

WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

Thirty-eighth report



World Health Organization

Geneva

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs Sw. fr. 132.– or US\$ 106.– (Sw. fr. 92.40 in developing countries). For further information, please contact Marketing and Dissemination, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 2476; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Contents

1. Introduction	1
2. General policy	2
2.1 Tenth International Conference of Drug Regulatory Authorities, China, Hong Kong, Special Administrative Region	2
2.2 Side meeting to the tenth International Conference of Drug Regulatory Authorities	2
2.3 International Conference on Harmonisation	3
2.4 Pharmacopoeial Discussion Group	3
2.5 Counterfeit drugs	3
2.6 Traditional medicine	4
2.7 Malaria	4
2.8 Biologicals	5
2.9 Risk related to transmissible spongiform encephalopathy	5
2.10 Bioequivalence	6
3. Quality control — specifications and tests	6
3.1 <i>The International Pharmacopoeia</i>	6
3.2 Dissolution test requirements	6
3.3 Specifications for radiopharmaceuticals	7
3.4 Quality specifications for antituberculosis drugs	7
3.5 Quality specifications for antimalarials	7
3.6 Pharmacopoeial monographs on antiretrovirals	8
3.7 Quality control — specifications for excipients	8
4. Quality control — International Reference Materials	8
4.1 International Chemical Reference Substances	8
4.2 International Infrared Reference Spectra	9
5. Quality control — national laboratories	10
5.1 Equipment for model quality control laboratories	10
5.2 External quality assurance assessment scheme	10
6. Quality assurance — good manufacturing practices	10
6.1 Excipients	10
6.2 Heating, ventilation and air conditioning	11
6.3 Herbal medicinal products	11
6.4 Validation	11
6.5 Water for pharmaceutical use	11
7. Quality assurance — inspection	12
7.1 Strengthening of Pharmaceutical Manufacturing Inspection project and development of training modules for inspectors	12
8. Quality assurance — distribution and trade-related	12
8.1 Good trade and distribution practices for pharmaceutical starting materials	12

8.2	WHO Pharmaceutical Starting Materials Certification Scheme for use in international commerce	13
8.3	WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce	13
9.	Quality assurance — risk analysis	14
9.1	New approach to inspections and manufacture	14
10.	Quality assurance — drug supply	14
10.1	Pre-qualification of manufacturers for the procurement and sourcing of pharmaceutical products	14
10.2	Pre-qualification of quality control laboratories	15
10.3	Pre-qualification of procurement agencies	15
10.4	Pre-qualification procedure for procurement of HIV/AIDS drugs	17
11.	International Nonproprietary Names programme	17
12.	Miscellaneous	18
12.1	Launch of <i>The International Pharmacopoeia</i> , Volume 5	18
12.2	Global Alliance for Quality of Pharmaceuticals	18
12.3	WHO Medicines Strategy 2004–2007	19
	Acknowledgements	20
	References	26
	Annex 1	
	Lists of available International Chemical Reference Substances and International Infrared Reference Spectra	28
	Annex 2	
	Good trade and distribution practices for pharmaceutical starting materials	36
	Annex 3	
	WHO pharmaceutical starting materials certification scheme (SMACS): guidelines on implementation	55
	Annex 4	
	Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies	79
	Annex 5	
	Guidelines for preparing a laboratory information file	89
	Annex 6	
	Procedure for assessing the acceptability, in principle, of procurement agencies for use by United Nations agencies	94

Annex 7	
Guidelines for the preparation of a procurement agency information file	104
Annex 8	
Interim guidelines for the assessment of a procurement agency (based on the draft model quality assurance system for procurement agencies)	108

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Geneva, 10–14 March 2003

Members*

Dr I. Abdoulaye, Assistant Professor, Faculté des Sciences de la Santé Université National de Bénin, Ministère de la Santé Publique, Cotonou, Bénin

Professor I. Addae-Mensah, Professor of Chemistry, University of Ghana, Legon, Accra, Ghana (*Chairperson*)

Dr D.L. Crawford, Drug Inspector, Barbados Drug Service, Bridgetown, Barbados

Ms F. Dansereau, Head, Inspection Unit, Health Products & Food Branch Inspectorate, National Coordination Center, Health Canada, Ottawa, Ontario, Canada (*Rapporteur*)

Dr F.R.Y. Fazli, Agha Khan Road, Islamabad, Pakistan

Dr J.A. Molzon, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD, USA (*Vice-Chairperson*)

Dr J.-L. Robert, Service du Contrôle des Médicaments, Laboratoire National de Santé, Luxembourg

Professor W. Wieniawski, Polish Pharmaceutical Society, Warsaw, Poland

Representatives of other organizations*

Council of Europe

Dr A. Artiges, Director, European Directorate for the Quality of Medicines & Dr J.H.McB. Miller, Head of Division III (Laboratory), European Directorate for the Quality of Medicines, Strasbourg, France

European Medicines Evaluation Agency (EMA)

Dr G. Wade & Dr E. Korakianiti, Quality of Medicines Sector, Canary Wharf, London, United Kingdom

International Pharmaceutical Federation (FIP)

Dr A.P. Sam, President, Industrial Pharmacy Section (International Pharmaceutical Federation), The Hague, The Netherlands

* Unable to attend: Mrs A.B. Moraes da Silva, Escola Nacional de Saúde Pública — FIOCRUZ, Coordenação de Cooperação Técnica, Rio de Janeiro, Brazil (Committee member); Mr R.W. Tribe, Chief GMP Auditor, Conformity Assessment Branch, Therapeutic Goods Administration, Woden, ACT, Australia (Committee member); European Chemical Industry Council (CEFIC), Brussels, Belgium; Japanese Pharmacopoeia, Tokyo, Japan; Pharmaceutical Inspection Convention (PIC), Geneva, Switzerland; United Nations Industrial Development Organization (UNIDO), Vienna, Austria; The World Bank, Washington, DC, USA; World Trade Organization (WTO), Geneva, Switzerland.

International Atomic Energy Agency (IAEA)

Dr D.V.S. Narasimhan, Industrial Applications and Chemistry Section, Department of Nuclear Sciences and Applications, Vienna, Austria

International Federation of Pharmaceutical Manufacturers Associations (IFPMA)

Dr O. Morin, Director, Regulatory and Scientific Affairs, Geneva, Switzerland

International Pharmaceutical Excipients Council (IPEC)

Professor H.J. de Jong, Chairman, IPEC-Europe, Strasbourg, France and Dr F. Milek, Chairperson, IPEC-Good Distribution Practice, Stuttgart, Germany

United Nations Children's Fund (UNICEF)

Dr P.S. Jakobsen, Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark

United States Pharmacopeia

Dr E. Fefer, Director, International Affairs & Dr R.L. Williams, Executive Vice President and Chief Executive Officer, Rockville, MD, USA

World Intellectual Property Organization (WIPO)

Ms K. Lee, Senior Counsellor, Office of the Special Counsel, Geneva, Switzerland

World Self-Medication Industry (WSMI), London, United Kingdom

Secretariat*

Professor H.R. Altorfer, Director, WHO Collaborating Centre for International Infra-red Reference Spectra International Infrared Reference Spectra, Department of Pharmacy, Swiss Federal Institute of Technology, Zurich, Switzerland
(*Temporary Adviser*)

Dr A. Asamoah-Baah, Executive Director, Health Technology and Pharmaceuticals Cluster, WHO, Geneva, Switzerland

Dr R. Balocco, Quality Assurance and Safety: Medicines, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Dr Chua Teck Hock, Director, Centre for Analytical Science, Pharmaceutical Laboratory, Health Sciences Authority, Singapore (*Temporary Adviser*)

Professor T.G. Dekker, Head, Research Institute for Industrial Pharmacy, Potchefstroom University for CHE, Potchefstroom, South Africa (*Temporary Adviser*)

Dr E. Ehrin, WHO Collaborating Centre for Chemical Reference Substances, Centrallaboratoriet, Kungens Kurva, Sweden (*Temporary Adviser*)

Dr M. Everard, Policy, Access and Rational Use, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Mr P. Graaff, Regional Adviser, WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt

* Unable to attend: Dr M. Chisale, Regional Adviser, WHO Regional Office for Africa, Harare, Zimbabwe; Dr Krisantha Weerasuriya, Regional Adviser, WHO Regional Office for South-East Asia, New Delhi, India; Dr Budiono Santoso, Regional Adviser, WHO Regional Office for the Western Pacific, Manila, Philippines.

Mr J. Hetzke, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Dr Yukio Hiyama, Chief, Third Section Division of Drugs, National Institute of Health Sciences, Tokyo, Japan (*Temporary Adviser*)

Dr S. Kopp, Quality Assurance and Safety: Medicines, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland (*Secretary*)

Miss Y. Maruyama, Traditional Medicine, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Dr S.V.K. Moideen, Head, Pharmaceutical Chemistry Laboratory, National Pharmaceutical Control Bureau, Ministry of Health, Petaling Jaya, Selangor, Malaysia (*Temporary Adviser*)

Dr K. Morimoto, Quality Assurance and Safety: Medicines, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Dr C. Ondari, Policy, Access and Rational Use, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Dr A.M. Padilla, Quality and Safety of Plasma Derivatives and Related Substances, Department of Blood Safety and Clinical Technology, WHO, Geneva, Switzerland

Dr J.D. Quick, Director, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Dr L. Rágo, Coordinator, Quality Assurance and Safety: Medicines, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Dr V. Reggi, Quality Assurance and Safety: Medicines, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Dr P. Vanbel, Quality Assurance and Safety: Medicines, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Mr A. van Zyl, Quality Assurance and Safety: Medicines, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Dr B. Vareldzis, Department of HIV/AIDS/STI, WHO, Geneva, Switzerland

Mr P.H. Vree, Maasdam, The Netherlands (*Temporary Adviser*)

Mr F. Wondemaneanehu, Quality Assurance and Safety: Medicines, Department of

预览已结束，完整报告链接和二维

<https://www.yunbaogao.cn/report/index/report?reportlo>